Abstract:Objective To evaluate the clinical significance of nuclear matrix protein 22 (NMP22) test in rapid diagnosis of bladder cancer.Methods From February 2009 to November 2011,803 patients and 200 healthy individuals were included in this multicenter study from four urology centers in China.They provided a urine sample for test of NMP22 protein using a point-of-care NMP22 BladderChek control kit (colloidal gold method).All tests were evaluated in a blinded fashion.Patients were divided into three groups.Group 1 included 392 patients of bladder cancer; group 2 included 411 patients who had benign urinary disease with non-bladder cancer history or non-bladder cancer; group 3 included 200 healthy individuals.The sensitivity and specificity of NMP22 test were analyzed compared with pathologic results using Pearson Chi-square test.Results The overall sensitivity and specificity of the NMP22 test were 69.6％ (273/392,95％ CI 64.9％-74.0％) and 84.9％ (519/611,95％CI 81.1％-87.6％),respectively.In group 1,337 patients had pathologic stage data,and the sensitivities of the NMP22 test for each stage were Ta-T1 69.6％ (165/237) and T2-T4 82.0％ (82/100),respectively; 322 patients had pathologic grade data,and the sensitivities for each grade were G1 60.5％ (72/119),G2 66.2％ (47/71) and G3 90.9％ (120/132),respectively.The specificities for patients of benign urinary disease,of non-bladder cancer history or nonbladder cancer and healthy individuals were 87.8％ (324/369),69.0％ (29/42) and 97.5％ (195/200),respectively.Conclusion NMP22 BladderChek control kit had high sensitivity and specificity in detection of bladder cancer,and it can be used in early detection and rapid diagnosis of bladder cancer.

Evaluation of Nuclear Matrix Protein22 (NMP22) in Urine for the Diagnosis of Bladder Transitional Cell Carcinoma

A clinical evaluation of nuclear matrix protein 22 in urine as an adjuvant diagnostic marker for transitional cell carcinoma of the upper urinary tract

[Significance of Urinary Nuclear Matrix Protein 22 in Diagnosis of Transitional Cell Carcinoma of Urinary Tract].

Studies on Urinary Nuclear Matrix Protein 22 Values in Patients with Transitional Cell Carcinoma of the Bladder

Study of the Expression of CK20 and Ki67 on Cystitis Glandularis of the Urinary Bladder

The Diagnostic and Prognostic Value of Nuclear Matrix Protein 22 in Bladder Cancer

Comparison between nuclear matrix protein 22 (NMP 22) test and voided urine cytology for detection of bladder cancer

Nuclear Matrix Protein 22 (Nmp22) Test In The Diagnosis Of Bladder Cancer: A Meta-Analysis

The clinical significance of urinary nuclear matrix protein 22 in screening postoperative recurrence of bladder cancer

An evaluation of NMP 22 urinary level and flow cytometry for diagnosing bladder transitional cell carcinoma.

Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma

NMP22 and BTA stat in the detection of bladder cancer

The Role of Nuclear Matrix Protein 22 Combined with Bladder Tumor Antigen Stat Test in Surveillance of Recurring Bladder Cancer.

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

[The Study of Relationship Between Nuclear Metrix Protein 22 Urinary Level and the Grade and Stage of Bladder Transitional Cell Carcinoma].

Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer

Detction of Cox-2 Protein and CK20 Mrna in Urine for the Diagnosis of Bladder Carcinoma

Nuclear matrix protein 22 in bladder cancer

Rapid Detection of Bladder Cancer Using a Point-of-care Nuclear Matrix Protein 22 BladderChek Control Kit: a Multicenter Clinical Trial

Comparison of Tumor Markers in the Early Detection of Bladder Cancer